Note: All times are Eastern Time unless otherwise noted.

### Friday, June 3

**Session 1**

**Location:** Arie Crown Theater  
**Time:** 2:15PM - 2:30PM  
**Session Type:** Education Session  
**Abstract #:**  
**Author:** Sunil S. Badve, MD (Panel Speaker)  
**Title:** Protein Profiling of Breast Cancer for Treatment Decisions

**Location:** S100a  
**Time:** 2:45PM - 3:00PM  
**Session Type:** Education Session  
**Abstract #:**  
**Author:** Judy Gichoya, MD, MS (Panel Speaker)  
**Title:** Bias and Ethical Issues in Artificial Intelligence

**Location:** S100bc  
**Time:** 2:47PM - 2:57PM  
**Session Type:** Education Session  
**Abstract #:**  
**Author:** Melinda Yushak, MD, PhD (Panel Speaker)  
**Title:** Tebentafusp for Uveal Melanoma

**Location:** E450  
**Time:** 3:12PM - 3:24PM  
**Session Type:** Oral Abstract Session  
**Abstract #:** 7504  
**Author:** Sharon M. Castellino, MD, MSc  
**Title:** A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNCS).

**Location:** S406  
**Time:** 6:09PM  
**Session Type:** Oral Abstract Session  
**Abstract #:** 6008  
**Author:** Nabil F. Saba, MD, FACP  
**Title:** Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL). A report from the Children’s Oncology Group phase 3 study, AHOD1531 (NCT 02166463).

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8059  
**Author:** Nisha Joseph, MD  
**Title:** Analysis of long-term outcomes in R-ISS stage 2 multiple myeloma with and without the presence of high-risk cytogenetics.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8061  
**Author:** Rujul H. Panikhet, MD (HMO Fellow)  
**Title:** Bortezomib, daratumumab, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8062  
**Author:** Nisha Joseph, MD  
**Title:** The impact of complex karyotype identified by conventional cytogenetics on survival outcomes of 1,000 patients with newly diagnosed multiple myeloma (NDMM).

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8063  
**Author:** Dabedochukwu Obiekwu, MBBS  
**Title:** Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8066  
**Author:** Shama Pirmohammed, BA  
**Title:** Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8067  
**Author:** Lana Khalil, MD (Post Doctoral Fellow)  
**Title:** Impact of metformin on clinical outcomes in advanced hepato-cellular carcinoma treated with immune checkpoint inhibitors.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8068  
**Author:** Shishir K. Maithel, MD, FACS  
**Title:** NEO-SAP: A phase II single-arm prospective feasibility study of nivolumab/paclitaxel/docetaxel/nab-paclitaxel for metastatic high-risk intrahepatic cholangiocarcinoma.

**Location:** Hall A  
**Time:** 9:00AM - 12:00PM  
**Session Type:** Poster Session  
**Abstract #:** 8069  
**Author:** Jill M. Binkley, PT, MSc, CLT (TurningPoint collaborator)  
**Title:** Racial disparity in breast cancer survivorship: Results of a qualitative research study to identify themes from a series of national healthcare provider live virtual forums.
Hall D-1
2:15PM Oral Abstract Session
Kevin Kalinsky MD, MS
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) in patients (pts) with unresistant or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). MANTAIN trial
Improving first-in-human and window-of-opportunity informed consent forms through participant feedback.
Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer.
Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer.
Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children's Oncology Group study AEWS0031
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Changes in opioid prescription, potential misuse, and substance use disorder in pediatric cancer survivors following the 2016 CDC opioid prescribing guideline
Accounting for the high enrollment of African Americans in Winship Cancer Institute’s myeloma clinical trials.

Hall A
2:30PM - 5:30PM Poster Session 1562
Anna Avinger
Improving first-in-human and window-of-opportunity informed consent forms through participant feedback.

Hall A
2:30PM - 5:30PM Poster Session 1502
Xu Ji, PhD
Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer.

E450
4:00PM - 5:30PM Education Session
Jonathon B. Cohen, MD (Chair)

S100a
4:15PM - 4:27PM Oral Abstract Session
Xu Ji, PhD

S404
5:30PM - 7:30PM Poster Discussion Session 12016
Tekiah McCary, BS

E451
5:30PM - 7:30PM Poster Discussion Session 8019
Sagar Lonial, MD, FACP

Winship ASCO Reception
The Westin Chicago River North
River North Riverbar
7:00PM - 9:00PM CDT

Sunday, June 5

Location | Time | Session Type | Abstract # | Author | Title
--- | --- | --- | --- | --- | ---
Hall A | 9:00AM - 12:00PM | Poster Session | 2070 | James Janopaul-Naylor, MD | Impact of systemic therapy regimen on survival of PCNSL
Hall A | 9:00AM - 12:00PM | Poster Session | 2604 | Mehmet Ace, MD | A phase 1 multi-dose-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (IDET-3).
Hall A | 9:00AM - 12:00PM | Poster Session | TPS1357 | R. Donald Harvey, PharmD, BCOP, FCCP | First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with selected advanced solid tumors
S103 | 8:30AM | Education Session | Maratha L. Arellano, MD (Speaker) | Training Program Directors’ Breakfast: Reviewing and Selecting Applicants for Interviews
S406 | 11:36AM | Oral Abstract Session | Madhav V. Dhodapkar, MBBS (Discussant) | Engaging T Cells in the Midst of the COVID-19 Pandemic
S504 | 12:00PM - 12:15PM | Education Session | Bree Eaton, MD (Speaker) | Modifying Radiotherapy to Reduce Late Effects in Metulloblastoma
E450 | 12:45PM - 1:00PM | Education Session | Ajay K. Nooka, MD, MPH, FACP (Chair) | The Role of Measurable Residual Disease Testing in Myeloma in the Quest for Cure
Arie Crown Theater | 12:57PM - 1:09PM | Oral Abstract Session | Kristin A. Higgins, MD (Discussant) | Optimizing Radiotherapy for Lung Cancer
E253b | 5:30PM - 6:45PM | Ticketed Session | Mylin Torres, MD | Meet the Professors: How Bad Is the Bone? Learning a Focused Radiology Review and Physical Exam in Patients With Spinal Metastases

Monday, June 6

Location | Time | Session Type | Abstract # | Author | Title
--- | --- | --- | --- | --- | ---
Hall A | 9:00AM - 12:00PM | Poster Session | 1074 | Jeffrey Aldrich, MD (HMO Fellow) | Real-world outcomes of Black women versus non-Hispanic White women with advanced triple-negative breast cancer treated with immune checkpoint inhibitors at an urban cancer center.
Hall A | 9:00AM - 12:00PM | Poster Session | TPS1117 | Kevin Kalinsky, MD | postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
Hall A | 9:00AM - 12:00PM | Poster Session | TPS1122 | Kevin Kalinsky, MD | Phase IIb study of BCL-2 inhibitor navitoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER+) breast cancer or advanced solid tumors.
Hall A | 9:00AM - 12:00PM | Poster Session | 10041 | Kelly C. Goldsmith, MD | Phase I trial of indinavir in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma. A new approach to neuroblastoma therapy consortium study.
Hall A 9:00AM - 12:00PM Poster Session TPS1127 Jane L. Meisel, MD

Hall A 9:00AM - 12:00PM Poster Session TPS8603 Suresh Ramalingam, MD
Phase 2 study of latiruzumab, a DLL1-targeting, half-life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).

Hall A 9:00AM - 12:00PM Poster Session 10038 Thomas Cash, MD, MSc
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Hall A 9:00AM - 12:00PM Poster Session 9128 Madhusmita Behera, PhD
Molecular testing and patterns of treatment in patients with NSCLC: An IASLC analysis of ASCO CancerLinQ Discovery Data.

Hall A 9:00AM - 12:00PM Poster Session 9017 Conor Steuer, MD
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

Hall A 9:00AM - 12:00PM Poster Session 9119 Jennifer Marks, MD
Analysis of MET exon 14 skipping mutations in non–small cell lung cancer (NSCLC) by histology and specific mutation.

Hall A 9:00AM - 12:00PM Poster Session Walid Shaib, MD (Chair)
Gastrointestinal Cancer—Colon and Anal

Hall D1 9:24AM Special Session Jonathan L. Kaufman, MD (Discussant)
Highlights of the Hematologic Malignancies - Plasma Cell Dyscrasia Track

E350 9:36AM - 9:48AM Clinical Science Symposium Olatunji B. Alese, MD (Discussant)
Exploring Barriers to Workplace Equity in Africa

S102 10:45AM Case-Based Panel Wendy Baer, MD (Moderator)
Loneliness: A Forgotten Challenge in Cancer Care

E450 4:24 PM - 4:36 PM Oral Abstract Session 1502 Xu Ji, PhD
Association between the Affordable Care Act Medicaid expansion and survival in young adults newly diagnosed with cancer.

E450 6:36PM - 6:48PM Education Session Ilana Graetz, PhD
Becoming a PRO: Improving Quality Through Digital Symptom Management

Online Posters

<table>
<thead>
<tr>
<th>Location</th>
<th>Time</th>
<th>Session Type</th>
<th>Abstract #</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Online</td>
<td>-</td>
<td>ePoster Session</td>
<td>e12529</td>
<td>Deepthi Kodali, MD</td>
<td>The Impact of obesity on triple negative breast cancer (TNBC) outcomes at a diverse academic cancer center.</td>
</tr>
<tr>
<td>Online</td>
<td>-</td>
<td>ePoster Session</td>
<td>e15075</td>
<td>Lisa Sudmeier, MD, PhD</td>
<td>Desmethylotriostat and brain metastasis-infiltrating CDS+ T cells.</td>
</tr>
<tr>
<td>Online</td>
<td>-</td>
<td>ePoster Session</td>
<td>e18005</td>
<td>Tony Zhuang, MD</td>
<td>Telotristat etil with PRRT in the treatment of well differentiated neuroendocrine tumors.</td>
</tr>
<tr>
<td>Online</td>
<td>-</td>
<td>ePoster Session</td>
<td>e18591</td>
<td>Chloe Lalonde, MD</td>
<td>Comparison of sociodemographic characteristics of a phase 1 clinical trial population at an NCI-designated comprehensive cancer center in the Southeast to catchment area.</td>
</tr>
<tr>
<td>Online</td>
<td>-</td>
<td>ePoster Session</td>
<td>e18786</td>
<td>Xin Hu, PhD</td>
<td>The impact of vertical integration of oncologists on cancer outcomes and healthcare costs among metastatic prostate cancer patients.</td>
</tr>
</tbody>
</table>